Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company’s web site at www.pvct.com.
- 18 years ago
QualityStocks
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…
-
QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare…
-
QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded…